The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples

Pathology

Volumn 48, Issue 1, 2016, Pages 60-71

  Bonar, Roslyn ^a   Favaloro, Emmanuel J ^b   Mohammed, Soma ^b   Ahuja, Monica ^b   Pasalic, Leonardo ^b,c   Sioufi, John ^a   Marsden, Katherine ^d  

^a RCPAQAP Haematology   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL HOBART HOSPITAL   (Australia)

Author keywords

anticoagulants; apixaban; coagulation; Haemostasis; laboratory testing; rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN; FRESH FROZEN PLASMA; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTI XA ASSAY; ARTICLE; BLOOD CLOTTING TEST; BLOOD EXAMINATION; DILUTE RUSSELL VIPER VENOM TIME; DIRECT THROMBIN INHIBITION ASSAY; DRUG BLOOD LEVEL; DRUG MONITORING; EX VIVO STUDY; HEMOSTASIS; HUMAN; IN VITRO STUDY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBIN TIME; AUSTRALIA AND NEW ZEALAND; BLOOD CLOTTING; DRUG EFFECTS; EVALUATION STUDY; REPRODUCIBILITY;

ANTICOAGULANTS; AUSTRALASIA; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; FACTOR XA INHIBITORS; HEMOSTASIS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; REPRODUCIBILITY OF RESULTS; RIVAROXABAN;

EID: 84975499203     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1016/j.pathol.2015.11.025     Document Type: Article

References (26)

1. A. Di Minno, G. Spadarella, D. Prisco, M. Franchini, R. Lupoli, and M.N. Di Minno Clinical judgement when using coagulation tests during direct oral anticoagulant treatment: a concise review Semin Thromb Hemost 39 2013 840 846
2. M. Cristhiam, Rojas-Hernandez, and D. Garcia The novel anticoagulants Semin Thromb Hemost 39 2013 117 126
3. N. Riva, and W. Ageno Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants Semin Thromb Hemost 41 2015 178 187
4. E.J. Favaloro, and G. Lippi Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors Semin Thromb Hemost 41 2015 208 227
5. E.J. Favaloro, and G. Lippi The new oral anticoagulants and the future of haemostasis laboratory testing Biochemia Medica (Zagreb) 22 2012 329 341
6. K. Senoo, and G.Y. Lip Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation Semin Thromb Hemost 41 2015 146 153
7. S. Schulman Treatment of venous thromboembolism with new oral anticoagulants according to patient risk Semin Thromb Hemost 41 2015 160 165
8. P.K. Chin Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants? Semin Thromb Hemost 41 2015 195 207
9. E.J. Favaloro, R. Bonar, J. Butler, and K. Marsden Laboratory testing for the new oral anticoagulants in Australia and New Zealand: a review of current practice Pathology 45 2013 435 437
10. R. Bonar, E.J. Favaloro, S. Mohammed, L. Pasalic, J. Sioufi, and K. Marsden The effect of dabigatran on haemostasis tests: a comprehensive assessment using in-vitro and ex-vivo samples Pathology 47 2015 355 364
11. T. Galanis, L. Thomson, M. Palladino, and G. Merli New oral anticoagulants J Thromb Thrombolysis 31 2011 310 320
12. T. Baglin The role of the laboratory in treatment with new oral anticoagulants J Thromb Haemost 11 Suppl 1 2013 122 128
13. M.M. Samama, and C. Guinet Review: laboratory assessment of new anticoagulants Clin Chem Lab Med 49 2011 761 772
14. M. Samama, G. Contant, T. Spiro, and et al. Laboratory assessment of rivaroxaban: a review Thromb J 11 2013 1 7
15. A. Tripodi Results expression for tests to measure the anticoagulant effect of new oral anticoagulants Thromb J 11 2013 9
16. A. Hillarp, K.M. Gustafsson, L. Faxalv, and et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays J Thromb Haemost 12 2014 1545 1553
17. J. Douxfils, A. Tamigniau, B. Chatelain, and et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban Thromb Haemost 110 2013 723 731
18. H. Mani Interpretation of coagulation test results under direct oral anticoagulants Int J Lab Hematol 36 2014 261 268
19. H. Mani, A. Kasper, and E. Lindhoff-Last Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations J Thromb Thrombolysis 36 2013 187 194
20. D.M. Adcock, and R. Gosselin Direct oral anticoagulants (DOAC) in the laboratory: 2015 review Thromb Res 136 2015 7 12
21. D. Tsakiris Direct oral anticoagulants - interference with laboratory tests and mechanism of action Semin Hematol 51 2014 98 101
22. G. Lippi, and E. Favaloro Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there a consensus? Clin Chem Lab Med 53 2015 185 197
23. H. Tran, J. Joseph, L. Young, and et al. New oral anticoagulants - a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis Intern Med J 44 2014 525 536
24. T. Baglin, D. Keeling, S. Kitchen, and British Committee for Standards in Haematology Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology Br J Haematol 159 2012 427 429
25. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J Thromb Haemost 2013; Jan 24 (Epub ahead of print)
26. H. Brinkman Global assays and the management of oral anticoagulation Thromb J 13 2015 9